Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 150,229
  • Shares Outstanding, K 44,711
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,770 K
  • 60-Month Beta 0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +35.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.94 +23.81%
on 05/04/20
4.39 -17.08%
on 05/21/20
+0.64 (+21.33%)
since 05/01/20
3-Month
1.30 +180.00%
on 03/18/20
4.39 -17.08%
on 05/21/20
+0.86 (+30.94%)
since 02/28/20
52-Week
1.18 +208.47%
on 10/23/19
4.39 -17.08%
on 05/21/20
+0.69 (+23.39%)
since 05/31/19

Most Recent Stories

More News
Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

SLNO : 3.64 (+8.33%)
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 3.64 (+8.33%)
Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity

Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS)

SLNO : 3.64 (+8.33%)
Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D.,...

SLNO : 3.64 (+8.33%)
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced...

SLNO : 3.64 (+8.33%)
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates

Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.

UTHR : 120.28 (+1.98%)
JAZZ : 119.37 (+0.04%)
USNA : 86.14 (+1.68%)
SLNO : 3.64 (+8.33%)
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

CORT : 15.16 (+0.13%)
PCRX : 44.58 (+1.43%)
ACRX : 1.2700 (-8.63%)
SLNO : 3.64 (+8.33%)
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has...

SLNO : 3.64 (+8.33%)
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 3.64 (+8.33%)
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock

Soleno Therapeutics, Inc. (SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the closing of...

SLNO : 3.64 (+8.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SLNO with:

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

2nd Resistance Point 4.01
1st Resistance Point 3.82
Last Price 3.64
1st Support Level 3.39
2nd Support Level 3.14

See More

52-Week High 4.39
Last Price 3.64
Fibonacci 61.8% 3.16
Fibonacci 50% 2.78
Fibonacci 38.2% 2.41
52-Week Low 1.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar